If you hadn't called the presentation a non event, I wouldn't be disagreeing with you, Investor. Whether there is any material information that is new to you or me is irrelevant. What is important is that this, to my knowledge, is the first presentation of the summary information from the Phase 2b/3 trial to an audience in Europe. It is not targeted to institutional investors, as was the TD Cowen presentation on Monday. It is targeted to opinion leaders - researchers and health care providers in the field of degenerative neurological diseases. It is being delivered not by a CEO but by a scientist, Timo Grimmer, well known in his field internationally and particularly in Europe. It is part of the first salvo by Anavex to get approval for Blarcamesine on the continent, and it comes at a time when there is little enthusiasm for LEQEMBI, whether or not that drug gets approved there over the next month or so. In my view it is a real event, not one that should be measured by whether it moves the stock at all on Monday.
News 
Market Data 
Discover 
